Advertisement
Organisation › Details
Domain Therapeutics (Group)
Domain Therapeutics is a biopharmaceutical company based in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G protein -coupled receptors (GPCRs), one of the most important classes of drug targets. Domain Therapeutics identifies and develops new drug candidates, allosteric modulators and biased ligands through its innovative approach and distinctive technologies. The company provides access to its technologies through research and collaborative agreements. It develops its own pipeline for components up to the stage of optimized lead product for major indications in central nervous system and metabolic disorders. In January 2014, the company established its subsidiary, Domain Therapeutics NA Inc., at the NEOMED Institute in Montreal, Canada. *
Start | 2008-12-01 renamed | |
Predecessor | Faust Pharmaceuticals S.A. | |
Industry | GPCR inhibitor | |
Industry 2 | CNS drug (neurological drug) | |
Person | Neuville, Pascal (Domain Therapeutics 200812c– CEO) | |
Person 2 | Malmezat, Stanislas-Léonard (Domain Therapeutics 202205 CFO) | |
Region | Illkirch | |
Country | France | |
Street | 850 Boulevard Sébastien Brant Bioparc | |
City | 67400 Illkirch | |
Tel | +33-3-9040-6150 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Domain Therapeutics (Group)
- [1] Domain Therapeutics S.A.. (4/17/24). "Press Release: Domain Therapeutics Appoints Sean A. MacDonald as Chief Executive Officer". Strasbourg, Motnreal, QC & Boston, MA....
- [2] Domain Therapeutics S.A.. (5/12/22). "Press Release: Domain Therapeutics Raises $42m Series A Financing to Accelerate Clinical Development of Its Best-in-Class and First-in-Class Immuno-oncology Programs". Strasbourg & Montréal, ON....
- [3] Domain Therapeutics S.A.. (1/13/20). "Press Release: Domain Therapeutics Secures €6 Million ($6.7M) Debt Financing". Strasbourg....
- [4] Domain Therapeutics S.A.. (9/11/19). "Press Release: Domain Therapeutics Invests in Ermium Therapeutics to Develop First-in-class CXCR4 Candidate for Autoimmune Diseases". Strasbourg....
- [5] Domain Therapeutics S.A.. (5/28/19). "Press Release: European Venture Capital Firm Seventure Partners Renews Its Support to Domain Therapeutics and Invests €3.5M ($3.9M) to Prepare the Next Growth Phase". Strasbourg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top